• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Citius Pharmaceuticals Inc.

    2/17/26 2:47:22 PM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTXR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Citius Pharmaceuticals, Inc.

    (Name of Issuer)


    Common Stock, $0.001 par value per share

    (Title of Class of Securities)


    17322U306

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    17322U306


    1Names of Reporting Persons

    CVI Investments, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,394,725.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,394,725.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,394,725.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  With respect to Row 6 and Row 8 above, Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.


    SCHEDULE 13G

    CUSIP No.
    17322U306


    1Names of Reporting Persons

    Heights Capital Management, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,394,725.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,394,725.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,394,725.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  With respect to Row 6 and Row 8 above, Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Citius Pharmaceuticals, Inc.
    (b)Address of issuer's principal executive offices:

    11 Commerce Drive, 1st Floor, Cranford, NJ 07016
    Item 2. 
    (a)Name of person filing:

    This statement is filed by the entities listed below, who are collectively referred to herein as "Reporting Persons," with respect to the shares of common stock of Citius Pharmaceuticals, Inc. (the "Company"), $0.001 par value per share (the "Shares"). (i) CVI Investments, Inc. (ii) Heights Capital Management, Inc.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of CVI Investments, Inc. is: P.O. Box 309GT Ugland House South Church Street George Town Grand Cayman KY1-1104 Cayman Islands The address of the principal business office of Heights Capital Management, Inc. is: 101 California Street, Suite 3250 San Francisco, California 94111
    (c)Citizenship:

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
    (d)Title of class of securities:

    Common Stock, $0.001 par value per share
    (e)CUSIP No.:

    17322U306
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by this Item 4(a) is set forth in Row 9 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The number of Shares reported as beneficially owned consists of (i) 799,934 Shares, and (ii) Shares issuable upon the exercise of warrants to purchase Shares (the "Warrants"). A portion of the Warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 4.99%, and the remainder of the Warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 9.99%. The Company's Quarterly Report on Form 10-Q, filed on February 13, 2026, indicates there were 22,376,427 Shares outstanding as of December 31, 2025.
    (b)Percent of class:

    9.9  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by this Item 4(c)(i) is set forth in Row 5 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     (ii) Shared power to vote or to direct the vote:

    The information required by this Item 4(c)(ii) is set forth in Row 6 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by this Item 4(c)(iii) is set forth in Row 7 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by this Item 4(c)(iv) is set forth in Row 8 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    CVI Investments, Inc.
     
    Signature:/s/ Sarah Travis
    Name/Title:Sarah Travis, Assistant General Counsel and Assistant Secretary of Heights Capital Management, Inc.
    Date:02/10/2026
     
    Heights Capital Management, Inc.
     
    Signature:/s/ Sarah Travis
    Name/Title:Sarah Travis, Assistant General Counsel and Assistant Secretary
    Date:02/10/2026

    Comments accompanying signature:  Heights Capital Management, Inc. serves as authorized agent of CVI Investments, Inc. pursuant to a Limited Power of Attorney, a copy of which was previously filed.
    Exhibit Information

    EXHIBIT INDEX EXHIBIT DESCRIPTION 24 Limited Power of Attorney* 99 Joint Filing Agreement* * Previously filed

    Get the next $CTXR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTXR

    DatePrice TargetRatingAnalyst
    12/30/2024$9.00Hold → Buy
    D. Boral Capital
    1/18/2022$4.00 → $6.00Buy
    HC Wainwright & Co.
    11/30/2021$4.00Buy
    Maxim Group
    More analyst ratings

    $CTXR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Mazur Leonard L

    4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

    9/23/25 4:05:24 PM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Vice Chairman Holubiak Myron Z

    4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

    8/12/25 4:51:56 PM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Webb Carol

    4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

    11/12/24 5:00:31 PM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTXR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Citius Pharmaceuticals Inc.

    SCHEDULE 13G/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

    2/17/26 2:47:22 PM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citius Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

    2/13/26 8:30:27 AM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Citius Pharmaceuticals Inc.

    10-Q - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

    2/13/26 8:00:57 AM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTXR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

    Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today reported financial results for the fiscal first quarter ended December 31, 2025, and provided a business update. "The first quarter of fiscal 2026 marked a pivotal inflection point for Citius Oncology with the successful U.S. commerci

    2/13/26 8:00:00 AM ET
    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

    Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2025, and provided a business update, including progress at its majority-owned subsidiary, Citius Oncology, Inc. (NASDAQ:CTOR). "I am thrilled to report that we have successfully transitioned to a revenue generating co

    2/13/26 8:00:00 AM ET
    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar

    Third international distribution agreement further advances global access strategy with major markets in Europe CRANFORD, N.J., Feb. 11, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced that it has entered into an exclusive distribution agreement with  Uniphar ("Uniphar"), a leading international healthcare services company, to support access to LYMPHIR™ (denileukin diftitox-cxdl) outside the United States. This agreement represents Citius Oncology's third international distribution partnership and further advances the Company's strategy to expand glob

    2/11/26 8:00:00 AM ET
    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTXR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citius Pharmaceuticals upgraded by D. Boral Capital with a new price target

    D. Boral Capital upgraded Citius Pharmaceuticals from Hold to Buy and set a new price target of $9.00

    12/30/24 7:26:29 AM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Citius Pharmaceuticals with a new price target

    HC Wainwright & Co. reiterated coverage of Citius Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $4.00 previously

    1/18/22 10:01:19 AM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Citius Pharmaceuticals with a new price target

    Maxim Group initiated coverage of Citius Pharmaceuticals with a rating of Buy and set a new price target of $4.00

    11/30/21 8:45:24 AM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTXR
    Financials

    Live finance-specific insights

    View All

    Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

    Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025 CRANFORD, N.J., Dec. 23, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal year ended September 30, 2025. "2025 was a pivotal year for Citius as we successfully launched LYMPHIR following its FDA approval, marking the first new systemic therapy for cutaneous T-cell lymphoma (CTCL) patients since 2018. This milestone reflects our ability to execute and our commitment t

    12/23/25 4:30:00 PM ET
    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

    Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL);Advanced ma

    12/27/24 5:00:00 PM ET
    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

    Management call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), today announced that it will host an investor call on Tuesday, August 13, 2024 at 8:30 am ET to discuss recent and upcoming developments. Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team. A question and answer period will follow management's discussion. Conference Call Details: Date: Tuesday, August 13, 2024 Time: 8:30 a.m. Eastern Time Dial In: 1-888-243-4451 (U.S. toll free) 1-412-542-4135 (international) Webcast: Register for the webcast here. A replay will

    8/12/24 8:00:00 AM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTXR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Citius Pharmaceuticals Inc.

    SC 13D/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

    11/27/24 4:05:31 PM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Citius Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

    5/8/24 2:22:56 PM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Citius Pharmaceuticals Inc.

    SC 13G - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

    1/31/24 2:08:26 PM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTXR
    Leadership Updates

    Live Leadership Updates

    View All

    After Major Oncology Conference, All Eyes Turn to Industry Innovation

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

    6/12/25 9:00:00 AM ET
    $CAH
    $CTOR
    $CTXR
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls

    CRANFORD, N.J., Nov. 5, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced the appointment of pharmaceutical industry veteran Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls (CMC). Mr. Creighton will be responsible for the global strategic regulatory and manufacturing development plans for Citius's five pipeline programs. "With two late P

    11/5/21 9:15:00 AM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citius Pharmaceuticals, Inc. Announces Appointment of Ilanit Allen as Vice President, Corporate Communications and Investor Relations

    CRANFORD, N.J., May 17, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR) today announced that Ilanit Allen has been appointed Vice President of Corporate Communications and Investor Relations, effective immediately.  In this newly created role, Ms. Allen will spearhead financial communication and investor activities, reporting to Myron Holubiak, President and Chief Executive Officer of Citius. "We are thrilled to welcome Ilanit to the Citius team as we advance our pipeline of first-in-class critical care products," stated Mr. Holubiak. "I am confident that Ilanit's extensive communications and investor relations experience, coupled with her financia

    5/17/21 12:30:00 PM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care